This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2003 Dec;48(12):3611; author reply 3613-5.

doi: 10.1002/art.11336.

Eligibility of rheumatoid arthritis patients seen in clinical practice for rheumatoid arthritis clinical trials: comment on the article by Sokka and Pincus

Yusuf Yazici, Doruk Erkan

PMID: 14674017
DOI: 10.1002/art.11336

Comment

Eligibility of rheumatoid arthritis patients seen in clinical practice for rheumatoid arthritis clinical trials: comment on the article by Sokka and Pincus

Yusuf Yazici et al. Arthritis Rheum. 2003 Dec.

. 2003 Dec;48(12):3611; author reply 3613-5.

doi: 10.1002/art.11336.

Authors

Yusuf Yazici, Doruk Erkan

PMID: 14674017
DOI: 10.1002/art.11336

No abstract available

PubMed Disclaimer

Comment on

Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis.
Sokka T, Pincus T. Sokka T, et al. Arthritis Rheum. 2003 Feb;48(2):313-8. doi: 10.1002/art.10817. Arthritis Rheum. 2003. PMID: 12571838

Similar articles

Improvement criteria--clinical and statistical significance: comment on the article by Pincus and Stein.
van Gestel AM, van Riel PL. van Gestel AM, et al. Arthritis Rheum. 2000 Jul;43(7):1658-60. doi: 10.1002/1529-0131(200007)43:7<1657::AID-ANR35>3.0.CO;2-A. Arthritis Rheum. 2000. PMID: 10902775 No abstract available.
Swollen joint count as a predictor of response to anti-tumor necrosis factor alpha therapy in rheumatoid arthritis: comment on the article by Sokka and Pincus.
Estrach C, Mpofu S, Thompson RN, Williams E, Abernethy VE, Moots RJ. Estrach C, et al. Arthritis Rheum. 2003 Dec;48(12):3611-3; author reply 3613-5. doi: 10.1002/art.11335. Arthritis Rheum. 2003. PMID: 14674016 No abstract available.
Add-on or step-up trials in rheumatoid arthritis: comment on the article by Boers.
Pincus T. Pincus T. Arthritis Rheum. 2004 Apr;50(4):1351; author reply 1351-2. doi: 10.1002/art.20161. Arthritis Rheum. 2004. PMID: 15077322 No abstract available.
Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
Farahani P, Levine M, Gaebel K, Thabane L. Farahani P, et al. Can J Clin Pharmacol. 2005 Fall;12(3):e254-63. Epub 2005 Nov 7. Can J Clin Pharmacol. 2005. PMID: 16278497 Review.
[Gold preparations in the treatment of rheumatoid arthritis].
Taukumova LA. Taukumova LA. Ter Arkh. 2002;74(2):82-7. Ter Arkh. 2002. PMID: 11899836 Review. Russian. No abstract available.

See all similar articles

Cited by

Early rheumatoid arthritis: pitfalls in diagnosis and review of recent clinical trials.
Cannella AC, O'Dell JR. Cannella AC, et al. Drugs. 2006;66(10):1319-37. doi: 10.2165/00003495-200666100-00002. Drugs. 2006. PMID: 16903767 Review.
Should Joint Deformity, which is More Common Than Swelling or Tenderness, be Assessed in all Rheumatoid Arthritis Patients and Databases?
Pincus T, Li T, Gibson KA. Pincus T, et al. ACR Open Rheumatol. 2025 May;7(5):e70025. doi: 10.1002/acr2.70025. ACR Open Rheumatol. 2025. PMID: 40390367 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information